Status:
COMPLETED
New Oral Anticoagulants (NOAC) in Stroke Patients
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Stroke
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascu...
Detailed Description
Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascu...
Eligibility Criteria
Inclusion
- signed informed consent form (ICF)
- existing or newly diagnosed AF
- recent (\< 3 month) stroke (ischemic or haemorrhagic) or TIA (=index event)
- treatment with NOACs or VKAs is continued, changed or initiated for prevention of ischemic events
Exclusion
- patients not able or unwilling to sign ICF
- patient is, in the opinion of the investigator, unlikely to comply with the scheduled follow-up visits or is unsuitable for any other reason
- patients who will not be anticoagulated
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
1023 Patients enrolled
Trial Details
Trial ID
NCT03826927
Start Date
March 1 2013
End Date
August 1 2021
Last Update
August 8 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Felix Platter Spital
Basel, Switzerland, 4002
2
Dep. of Neurology, Hospital of the University of Basel
Basel, Switzerland, 4031